A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy

INTRODUCTION: Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop. Here, we describe a severe case of sclerosing cholangitis-like irAE. We report the use of 3 immunosuppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirasawa, Yuya, Yoshimura, Kiyoshi, Matsui, Hiroto, Kubota, Yutaro, Ishida, Hiroo, Arai, Jun, Sakaki, Masashi, Oguro, Nao, Shida, Midori, Taniguchi, Makoto, Hamada, Kazuyuki, Ariizumi, Hirotsugu, Ishiguro, Tomoyuki, Ohkuma, Ryotaro, Sambe, Takehiko, Horiike, Atsushi, Imamura, Chiyo K., Shiozawa, Eisuke, Wada, Satoshi, Tsurutani, Junji, Iwamoto, Sanju, Uchida, Naoki, Kiuchi, Yuji, Tate, Genshu, Kobayashi, Shinichi, Tsunoda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202549/
https://www.ncbi.nlm.nih.gov/pubmed/34114983
http://dx.doi.org/10.1097/MD.0000000000025774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202549/
https://www.ncbi.nlm.nih.gov/pubmed/34114983
http://dx.doi.org/10.1097/MD.0000000000025774

Ejemplares similares